Press Releases.

Volition Appoints Mickie Henshall as an Independent Director

VolitionRx Limited Announces Second Quarter 2022 Financial Results and Business Update

Volition Announces U.S. Clinical Study for NETs

VolitionRx Limited Schedules Second Quarter 2022 Earnings Conference Call and Business Update

Volition Appoints DXOCRO to Spearhead U.S. FDA Strategy

VolitionRx Awarded $1.5 Million in Non-Dilutive Funding

VolitionRx Limited Announces Closing of $6.9 Million Underwritten Public Offering of Common Stock

VolitionRx Limited Announces Pricing of $6 Million Underwritten Public Offering of Common Stock

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock

New NETs Data Presented at International Society on Thrombosis and Haemostasis (ISTH) Congress

Volition Achieves CE Mark for Nu.Q® NETs Test

VolitionRx Limited Announces First Quarter 2022 Financial Results and Business Update